Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.
Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T. Inker LA, et al. Among authors: vonesh ef. J Am Soc Nephrol. 2019 Sep;30(9):1735-1745. doi: 10.1681/ASN.2019010007. Epub 2019 Jul 10. J Am Soc Nephrol. 2019. PMID: 31292197 Free PMC article.
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K. Levey AS, et al. Am J Kidney Dis. 2020 Jan;75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009. Epub 2019 Aug 28. Am J Kidney Dis. 2020. PMID: 31473020
Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.
Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA. Greene T, et al. Among authors: vonesh ef. J Am Soc Nephrol. 2019 Sep;30(9):1756-1769. doi: 10.1681/ASN.2019010009. Epub 2019 Jul 10. J Am Soc Nephrol. 2019. PMID: 31292198 Free PMC article.
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression.
Neuen BL, Tighiouart H, Heerspink HJL, Vonesh EF, Chaudhari J, Miao S, Chan TM, Fervenza FC, Floege J, Goicoechea M, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PK, Locatelli F, Maes BD, Perrone RD, Praga M, Perna A, Schena FP, Wanner C, Wetzels JFM, Woodward M, Xie D, Greene T, Inker LA; CKD-EPI Clinical Trials. Neuen BL, et al. Among authors: vonesh ef. J Am Soc Nephrol. 2022 Feb;33(2):291-303. doi: 10.1681/ASN.2021070948. Epub 2021 Dec 3. J Am Soc Nephrol. 2022. PMID: 34862238 Free PMC article.
Letter by Inker et al Regarding Article, "Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure".
Inker LA, Heerspink HJL, Vonesh EF, Greene T. Inker LA, et al. Among authors: vonesh ef. Circ Heart Fail. 2022 Mar;15(3):e008983. doi: 10.1161/CIRCHEARTFAILURE.121.008983. Epub 2022 Jan 11. Circ Heart Fail. 2022. PMID: 35014564 No abstract available.
95 results